Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
His tenure will be for a period of five years, effective from 14 June 2025, to 13 June 2030.
The appointment is expected to provide continued strategic leadership and drive growth initiatives for the company in the coming years.
Abbott India is one of the leading multinational pharmaceutical companies in India and sells its products through independent distributors primarily within India.
Abbott India’s standalone net profit climbed 15.79% to Rs 415.27 crore on 7.62% increase in revenue from operations to Rs 1,757.15 crore in Q2 FY26 over Q2 FY25.
Shares of Abbott India shed 0.63% to currently trade at Rs 29,536.05 on the BSE.
Profit before tax (PBT) stood at Rs 545.93 crore in Q2 FY26, up 13.87% year on year (YoY).
Total expenses increased 5.55% to Rs 1,281.17 crore in Q2 FY26 as against Rs 1,213.72 crore posted in same quarter last year. The cost of materials consumed stood at Rs 162.59 crore (down 5.50% YoY), employee benefit expense was at Rs 158.98 crore (up 7.85% YoY) and finance cost was at Rs 7.55 crore (up 202% YoY) during the period under review.
Shares of Abbott India rose 0.77% to settle at Rs 29,593.20 on the BSE.
Abbott India Ltd is up for a third straight session today. The stock is quoting at Rs 30500, up 1.79% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.5% on the day, quoting at 25018.1. The Sensex is at 81649.92, up 0.55%. Abbott India Ltd has slipped around 1.5% in last one month.
Meanwhile, Nifty Pharma index of which Abbott India Ltd is a constituent, has slipped around 0.69% in last one month and is currently quoting at 21756.35, down 0.19% on the day. The volume in the stock stood at 2333 shares today, compared to the daily average of 10331 shares in last one month.
The PE of the stock is 43.81 based on TTM earnings ending June 25.